Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (1478)	10/29/1998 8:37:00 PM
From: crysball	Respond to of 1491

GOOD NEWS for PARS The FDA today approved the use of Tamoxifen to prevent breast cancer tumors in women at High Risk. In the news release the American Cancer Society estimated there are 3 million women in the USA between 35 and 59 considered at 'HIGH RISK' for Breast Cancer due to family history, genetics, etc. Finally, some FDA action to address prevention for this dreaded disease. The FDA urged Physicians to use careful judgement in selecting those patients at high risk, but this portends well for Pharmos and their Tamoxifen Methiodide analogue......if they can ever get sufficient cash flow to bring it off the back burner for a Phase 1. Ariella, my compliments to you for the excellent & continuous stream of quality contribution you make to this thread. Perhaps you might offer some insight into the plans for Tamoxifen It would seem the market maker had a field day today, moving the stock down 5/32 on such low volume.........looks like more bargain hunting ahead as we run into the quarterly report.

To: Ariella who wrote (1478)	10/29/1998 8:49:00 PM
From: crysball	Read Replies (2) \| Respond to of 1491

More on Tamoxifen From the description of the patient population at high risk for breast cancer could one also imply the patents will be on long term medication, since the risk factors themselves [genetics/ family history/etc] are not changed by taking Tamoxifen ......hence a very long term market........i.e. if a high risk candidate for breast cancer starts taking Tamoxifen at age 35 she could conceivably continue on the medication for 25 years? Perhaps one of PARS Physician contributors could comment on today's FDA release ?